Adverum Biotechnologies (NASDAQ:ADVM) and Twist Bioscience (NASDAQ:TWST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares Adverum Biotechnologies and Twist Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adverum Biotechnologies -4,505.40% -30.98% -28.63%
Twist Bioscience -204.63% -548.66% -68.71%

Analyst Recommendations

This is a summary of recent ratings for Adverum Biotechnologies and Twist Bioscience, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adverum Biotechnologies 0 4 2 0 2.33
Twist Bioscience 0 1 3 0 2.75

Adverum Biotechnologies presently has a consensus target price of $8.13, suggesting a potential downside of 29.71%. Twist Bioscience has a consensus target price of $26.33, suggesting a potential downside of 9.88%. Given Twist Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Twist Bioscience is more favorable than Adverum Biotechnologies.

Insider and Institutional Ownership

61.0% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 18.5% of Twist Bioscience shares are held by institutional investors. 4.2% of Adverum Biotechnologies shares are held by company insiders. Comparatively, 29.4% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Adverum Biotechnologies and Twist Bioscience’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adverum Biotechnologies $1.61 million 457.96 -$72.63 million ($1.18) -9.80
Twist Bioscience $25.43 million 37.28 -$71.23 million ($25.51) -1.15

Twist Bioscience has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Twist Bioscience beats Adverum Biotechnologies on 8 of the 13 factors compared between the two stocks.

Adverum Biotechnologies Company Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.



Receive News & Ratings for Adverum Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Adverum Biotechnologies and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *